A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

Exclusion Criteria

• •1. At the time of either the screening or baseline visit, decision has already been made to deliver within the next 7 days, for any indication.
• •2. Known non-reassuring fetal status based upon antepartum testing (e.g., NST/CTG or BPP) at or within 7 days before the baseline visit.
• •3. Known fetal anomaly likely to result in intrauterine fetal demise or neonatal death within the first 30 days of life.
• •4. Participating in another ongoing interventional clinical study at screening or planning to participate in another contemporaneous interventional clinical study while participating in this study.